article thumbnail

Partnering for success in early phase clinical development

BioPharma Drive: Drug Pricing

Early-phase clinical trials, including phase 1 and some phase 2a studies, serve as a pivotal step for biotech companies, laying the foundation for a drug candidate’s journey to market.

article thumbnail

The rising impact of biomarkers in early clinical development

Drug Target Review

Prior to being validated, the FDA will still consider biomarkers in the marketing approval process as a reasonably likely surrogate endpoint or candidate surrogate endpoint. Biomarkers can play a crucial role throughout clinical development, especially in early phases.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Centers of excellence or product-centric BizDevOps managed services?

BioPharma Drive: Drug Pricing

As novel therapeutics become more complex — and costly — to bring to market, drug developers are looking to unified clinical development platforms to streamline operations.

article thumbnail

Harnessing AI and Real-World Data: The Future of Clinical Development

PPD

Our comprehensive approach, integrating various aspects of drug development, such as clinical development, post-approval activities and market access, ensures optimal utilization of tools and strategies. Ready to learn more about convergence of real-world data and technology for clinical trials?

article thumbnail

Carl Sailer on AI, market trends, and strategic planning in biotech

Fierce BioTech

Carl Sailer is Vice President of Full Service Solutions at Syneos Health®, a leading fully integrated biopharmaceutical solutions organization providing clinical development and commercialization s | In this conversation with Fierce Biotech, we explore the ever-evolving biotech landscape.

article thumbnail

Market Insights: What’s Driving the Shift Toward FSP Models in Clinical Development?

Fierce BioTech

As advancements in medical science progress, clinical research and development (R&D) are subject to more sophisticated and complex study designs and protocols that require precise global coordi | Market Insights: What’s Driving the Shift Toward FSP Models in Clinical Development?

article thumbnail

Why early market access planning is crucial in CGT commercial strategy

Fierce BioTech

Experts recommend that CGT manufacturers proactively design a comprehensive market access strategy early in clinical development and commercial planning timelines, ideally more than three years pri | CGT companies should consider developing a market access strategy early in clinical development, ideally more than three years prior to launch.